Indivior Pharmaceuticals, Inc. (INDV) SEC Filings & Earnings Calls

Merger could be delayed or challenged by shareholder litigation.

“Two complaints filed in NY Supreme Court; demand letters received.”

Dividend payment is contingent on merger closing; if merger fails, no dividend is paid.

“Indivior will not pay the Special Dividend if the Merger is not completed for any reason.” · word for word

Supply chain transition risk during validation of new supplier's manufacturing process.

“Obligations under new supplier agreement enforceable only after validation.”

Activist exit / loss of large holder support

“As a result of the Transactions on or prior to August 10, 2026, the Reporting Persons ceased to be the beneficial owners of more than five percent of the Common Stock on such date.” · word for word

Activist exit / loss of large holder support

“As a result of the Transactions on or prior to August 10, 2026, the Reporting Persons ceased to be the beneficial owners of more than five percent of the Common Stock on such date.” · word for word

Merger completion risk

“The merger is subject to conditions, some or all of which may not be satisfied, or completed on a timely basis, if at all. Failure to complete the merger could have material adverse effects on our business.” · word for word

Pipeline failure

“During the six months ended June 30, 2026, Indivior made the decision to cease Phase 3 development of INDV-6001 and not advance INDV-2000 internally. The Company is not currently pursuing any pipeline activities.” · word for word

Product concentration risk

“SUBLOCADE accounted for 74% and 74% of our net revenue for the three and six months ended June 30, 2026, respectively.” · word for word

Merger integration risk with Supernus expected to close in Q4 2026

“We look forward to closing our proposed merger with Supernus, which is expected in the fourth quarter.”

Dependence on SUBLOCADE for revenue growth; single product concentration

“SUBLOCADE represents ~74% of total revenue (253/343), up from 69% in prior year.”

Merger completion risk: requires stockholder and regulatory approvals; may not close on expected timeline.

“Risk that the proposed merger may not be completed in a timely manner or at all; failure to obtain required approvals.” · word for word

Integration risk: difficulties and costs of integrating two businesses; potential diversion of management attention.

“Difficulties and costs of integrating the two businesses; diversion of management's attention and resources.” · word for word

Integration risk from large merger

“Merger with Supernus, combined company integration”

Increased leverage from $650M debt and $1B special dividend

“$650 million senior secured term loan facility and $1B special dividend”

Potential loss of scientific leadership and R&D continuity risk.

“Elimination of CSO role and departure of Dr. Heidbreder.”

ASR exposes company to stock price volatility during settlement period

“final number of shares repurchased will be determined based on the volume weighted average price” · word for word

Litigation risk - Dental MDL

“As of April 28, 2026 approximately 1,900 cases naming approximately 25,000 plaintiffs have been consolidated in multi-district litigation in the Northern District of Ohio.” · word for word

Pipeline failure risk

“Indivior does not intend to pursue Phase 3 development of INDV-6001 ... INDV-2000 did not meet the primary endpoint of 'no treatment failure.'” · word for word

Concentration risk - SUBLOCADE

“SUBLOCADE accounted for 73% and 66% of our net revenue for the three months ended March 31, 2026 and 2025, respectively.” · word for word

Pipeline setbacks: INDV-6001 and INDV-2000 discontinued, reducing future growth optionality

“Indivior does not intend to pursue Phase 3 development of INDV-6001; INDV-2000 did not meet primary endpoint” · word for word

Dependence on SUBLOCADE for revenue growth; concentration risk

“SUBLOCADE net revenue represents 73% of total net revenue”

OPVEE discontinuation

“In August 2025, the Company eliminated the sales force and operational structure for OPVEE.” · word for word

Competition in OUD market

“greater than expected impacts from competition” · word for word

Regulatory/legal risks

“regulatory or legal matters” · word for word

Significant increase in debt ($500M); potential dilution from conversion; interest expense; subordination to secured debt.

“$500M principal of 0.625% Convertible Senior Notes due 2031; initial conversion price ~$41.66; subordination to secured debt.”

Significant increase in debt ($500M); potential dilution from conversion; interest expense.

“$500M principal of 0.625% Convertible Senior Notes due 2031.”

Significant increase in debt ($500M); potential dilution from conversion; interest expense.

“$500M principal of 0.625% Convertible Senior Notes due 2031.”

Product concentration risk on SUBLOCADE

“SUBLOCADE accounted for 69% of total net revenues in 2025.”

Debt covenant risk

“The first covenant requires that the Total Leverage Ratio of the consolidated borrower group to be less than 3.0 to 1.0 (through September 30, 2026)”

Tariff exposure on imported inputs

“Tariffs apply to both SUBLOCADE and SUBOXONE Film but with moderate impact based on the latest tariffs” · word for word

Litigation risk (dental injury lawsuits)

“The Company has been named as a defendant in numerous lawsuits alleging that SUBOXONE Film was defectively designed and caused dental injury” · word for word

DOJ liability paid in full; no further exposure

“Concluded legacy DOJ matter on Nov 20, 2025, paying $295M in full.”

Execution risk from corporate restructuring and debt amendment.

“Amendment to Note Purchase Agreement and new governance documents.”

Revenue decline due to SUBOXONE Film pressure; competition risk.

“U.S. SUBOXONE Film pressure; overall revenue down 3% YoY.”

No material risk; routine compensation adjustment.

“No adverse events or departures disclosed.”

Removal of significant legal liability reduces risk profile.

“Legacy DOJ matter concluded; resolution agreement terminated.”

Re-domestication introduces execution and regulatory risks, but may provide governance benefits.

“Proposed re-domestication from UK to Delaware via scheme of arrangement.”

Generic competition for SUBOXONE Film

“decline in SUBOXONE Film due to generic competition” · word for word

Restructuring execution risk

“Optimization of Rest of World (ROW) Business... Discontinued the Sales and Marketing Support of OPVEE” · word for word

Restructuring execution risk

“The optimization is expected to result in total charges ranging from $30 million to $50 million, primarily relating to headcount reductions, real estate consolidations, asset impairments, consulting services, and contractual termination and related costs.”

Competitive pressure on legacy products

“U.S. net revenue from other products declined $19 million and $50 million in the three and nine months ended September 30, 2025, reflecting the impact of increased competitive activity resulting in lower pricing and market share in the U.S. for SUBOXONE Film.” · word for word